Last reviewed · How we verify
OCPs
OCPs (oral contraceptive pills) represent a foundational hormonal contraceptive class developed and studied extensively by the University of Adelaide and multiple academic institutions. The mechanism involves synthetic estrogen and progestin compounds that suppress ovulation through inhibition of gonadotropin-releasing hormone (GnRH), preventing the luteinizing hormone (LH) surge required for ovulation. While no FDA-approved indication is formally attributed to this University of Adelaide program, OCPs are well-established therapeutics with extensive clinical validation across contraception, dysmenorrhea, PCOS management, and amenorrhea treatment, as evidenced by 14 completed or ongoing clinical trials spanning Phase 2 through Phase 4 research. The University of Adelaide's research portfolio demonstrates particular focus on mechanistic understanding—including drug-drug interactions with cannabidiol, effects on ovarian blood flow in PCOS, and neurosteroid modulation—rather than novel formulation development. Commercial significance is substantial: OCPs represent a multi-billion-dollar global market with near-universal insurance coverage and generic competition, though the University of Adelaide program appears primarily investigational rather than commercialized. Pipeline expansion includes exploration of contraceptive efficacy in complex populations (poor ovarian responders, dysmenorrhea-to-chronic-pain progression) and safety profiling in comorbid conditions (asthma, neurological function).
At a glance
| Generic name | OCPs |
|---|---|
| Sponsor | University of Adelaide |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- OCPs CI brief — competitive landscape report
- OCPs updates RSS · CI watch RSS
- University of Adelaide portfolio CI